Today news is just a sliver of what is going on with Medolife.
Medolife has been researching Escozine® as a potential treatment for COVID-19 in clinical research programs in both the United States and the DR. The Company has completed numerous safety and efficacy studies on the drug, and filed a final data set with the US Food and Drug Administration (FDA) as it relates to an Investigational New Drug (IND) filing on Escozine®. The Company is in the process of registration for medical ethics committee approval to conduct double-blind placebo human studies on Escozine®, which would mark a substantial step forward in Escozine’s path toward worldwide registration and adoption.
Once Escozine is approved for use for Covid-19 therapeutic, the domino effect will come into play.
There are many potential uses for Escozine and some are in research and development for future FDA submission and approval.
Research and Development
Natural Products in Development:
Escozine™ Spray Solution
Escozine™ Enema Solution
Medical Grade Products in Development for FDA Approval:
Escozine GNP-1™
ESCOZINE GNP-1™ is in research and development as an advanced anti-cancer drug. Polarized gold nanoparticles combined with a novel peptide extracted from the Caribbean Blue Scorpion venom, potentiates the bioactive compound and increases the effectiveness of the natural compound up to synthetic drug strength by efficiency. The result is a new category of powerful medications without considerable side effects.
Medolife™ is presently preparing to apply to the FDA (Food and Drug Administration) for clinical trials in the United States for ESCOZINE GNP-1™.
Patch – preparing to apply for FDA approval
Four types of Escozine patch are in the research and development stage and these will provide an easy, targeted and effective delivery solution for the product. The enhanced transdermal technology system will allow Escozine’s small molecule peptide to pass through skin’s barrier layer of stratum corneum directly to the target location. The patches that are being developed are:
Breast Patch
Prostate Patch
Skin Patch
Immune Enhancer Patch
Injectable – preparing to apply for FDA approval
Medolife expects to have promising results with an injectable version which is currently in research and development. The product will be directly injected into the tumor by normal injectable methods or by Electrophoresis.
In many cases, doctors cannot perform necessary surgery or use chemotherapy because of tumor location or the patient’s health condition.
Escozine Injectable can become a useful tool for doctors and surgeons.
I.V (Intravenous) – preparing to apply for FDA approval
For those who require a more monitored treatment process, the intravenous version will provide an effective solution for doctors. This version of the product is in research and development in cooperation with Synthesis Laboratories.
